Dr. reddy's laboratories announces the launch of ephedrine sulfate injection usp, 50 mg/ml, single-dose vial in the u.s. market

Hyderabad, india & princeton, n.j.--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, along with its subsidiaries together referred to as “dr. reddy's”) today announced the launch of ephedrine sulfate injection usp, 50 mg/ml, a therapeutic equivalent generic version of akovaz® (ephedrine sulfate injection) injection, 50 mg/ml approved by the u.s. food and drug administration (usfda). the akovaz® brand and generic market had u.s. sales of app
RDY Ratings Summary
RDY Quant Ranking